The product is released as a pharma-grade 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidin-5-yl-methanol, identified by CAS 147118-36-3, molecular formula C16H20FN3O3S, and molecular weight 353.41 g/mol. The substance is a white to off-white crystalline powder intended for oral and injectable pharmaceutical manufacturing routes where the C5 primary alcohol is either carried forward as a synthetic handle or converted to the corresponding aldehyde, halide, or sulfonate ester. Although the product descriptor sometimes appears with the truncated spelling “pyriminl,” the CAS and IUPAC descriptions retain “pyrimidin.” The free alcohol is not equivalent to the final calcium heptenoate salt: it lacks the 3,5-dihydroxyheptenoic acid side chain and the calcium counterion, and therefore does not exhibit the same HMG-CoA reductase inhibition, aqueous solubility, or salt-dependent compaction behavior.

Model coding across manufacturers is subordinate to the CAS registry number and IUPAC identifier. Purchase specifications should require CAS 147118-36-3 and the alternative description {4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}methanol because supplier-specific product codes may change without chemical equivalence. The release specification framework for tablet, capsule, granule, and injection work is built on compendial general chapters and ICH guidance rather than on a single product monograph, because no individual public monograph has been established for this intermediate.

The table is a specification-test menu rather than a batch certificate; each manufacturer must justify acceptance limits from process capability, stability data, and the intended route of administration. For oral solid forms, endotoxin and sterility are omitted; for injectable forms they are added.

When the 5-ylmethanol oxidation state controls downstream process windows

The C5 primary alcohol separates this product from the corresponding 5-carboxaldehyde, CAS 147118-37-4, and the 5-carboxylic acid, CAS 147118-35-2. The carboxaldehyde is a direct Wittig or Horner-Wadsworth-Emmons partner for side-chain extension, but it is more sensitive to air oxidation, hydrate formation, and self-condensation. The methanol form is selected when downstream activation is staged rather than immediate: the alcohol can be oxidized to the aldehyde under controlled conditions, or converted to a halide or sulfonate ester for phosphonium salt formation. This difference is not trivial in production. If residual alcohol remains in an aldehyde intermediate, it can quench the ylide and reduce coupling yield; if over-oxidation generates the carboxylic acid, aqueous workup may become complicated by emulsification and charge rejection. An HPLC method operated under USP <621> can resolve the alcohol, aldehyde, and acid using a C18 column and phosphate-buffered acetonitrile, provided relative retention times are established with reference standards.

Published data for this specific configuration is limited, but process-development reports for closely related pyrimidine alcohols describe exothermic oxidation in glass-lined reactors with jacket temperature held below -50 °C for Swern-type activation. Endpoint control should target residual alcohol at ≤0.5% relative to the product before entering the next stage. The acid form may be selected if salt formation or esterification is required, while the aldehyde may be selected if direct C–C bond formation is the rate-limiting step.

For tablet and capsule manufacture, the free alcohol may require particle-size modification before direct compression. The key physical properties are particle size distribution by laser diffraction under USP <429>, bulk and tapped density under USP <616>, and flow behavior through a shear cell. If the d90 exceeds 250 µm, dry granulation or wet granulation is usually required. In high-shear granulation, the granulation endpoint should be controlled by impeller torque and power consumption rather than a fixed water volume, because the primary alcohol can interact with water and produce overwetting. Tablet press parameters such as compression force, precompression, and turret speed must be established from experimental compaction profiles; direct substitution from the final calcium salt is not valid.

What Limits Sterile Injectable Release for a Pyrimidinyl Alcohol Without a Terminal Carboxylate?

Injectable processing imposes stricter requirements than oral solid processing. The free alcohol lacks an ionizable carboxylate, so pH adjustment alone may not achieve the solubility needed for a simple aqueous injectable. Co-solvent systems such as polyethylene glycol or cyclodextrin may be required, but compatibility data must be generated; published data for this exact configuration is limited. Endotoxin control is critical when water is used in the final purification or equipment rinse. Depyrogenation of equipment by dry heat or chemical inactivation must be validated, and the API must meet bacterial endotoxin limits under USP <85> before release for injectable use.

Sterile filtration through a 0.22 µm PVDF or PES filter is common, but filter compatibility and drug binding must be tested under 21 CFR 211.67. If the primary alcohol is not stable to terminal moist-heat sterilization, aseptic processing under 21 CFR 211.113(b) is required. Residual solvent limits under ICH Q3C(R8) are also route-dependent: a lot that is acceptable for oral administration may not be acceptable for injection because the permitted daily exposure for Class 2 solvents is lower in parenteral products. Particulate matter must meet USP <788> after reconstitution or terminal filtration; if the API is milled to support oral dosing, the same lot may not be acceptable for injectable use without further purification.

The oral and injectable routes therefore require separate release designations. Oral-grade material should be tested for microbial limits under USP <61> and <62>, while injectable-grade material requires endotoxin, particulate matter, and sterility when the final product is sterile. Particle size control is also route-specific: oral dry granulation may tolerate a broader distribution, while injectable processing generally requires finer, filterable material with low bioburden.

Release-test differentiation by route of administration

The distinction matters in specification setting: the methanol is not a simple substitute for the final calcium salt in direct compression or injectable formulation. Pharmacopoeial assays for the final salt are not applicable; the methanol requires its own impurity markers, including the des-fluoro alcohol, N-demethylated sulfonamide, and oxidation products such as the C5 carboxaldehyde and C5 carboxylic acid. Each batch should be tracked by HPLC retention times and relative response factors established under ICH Q2(R1).

Residual solvents must be controlled with reference to the actual manufacturing route. If halogenated solvents are used during alcohol activation, they require Class 2 or Class 1 assessment under ICH Q3C(R8). The N-methylsulfonylamino group may hydrolyze under forcing aqueous base at elevated temperature, so aqueous washes should be confined to controlled pH and time. Incoming raw material testing under 21 CFR 211.84 should include identity, assay, related substances, residual solvents, and elemental impurities; additional endotoxin and particulate matter tests are route-dependent.

The compound may be stored in tightly closed HDPE or glass containers under nitrogen with desiccant. Primary alcohols of similar structure can undergo slow oxidation, so headspace oxygen and temperature should be controlled during long-term storage. For solid oral development, experimental compaction and excipient compatibility remain the decisive controls; for injectable development, filter compatibility, endotoxin, and particulate matter define release. The two uses are not interchangeable simply by changing the label.